Chronic Kidney Disease

Beyond HbA1c: Take a Global Approach to Type 2 Diabetes Management, Use all the Tools
July 01, 2022

Drs Mikhail Kosiborod and Neil Skolnik discuss this unique moment in the history of T2D management that offers treatments to address its broad cardiometabolic impact.

Empagliflozin Could Reduce Risk of Kidney Stones in Patients with Type 2 Diabetes
June 17, 2022

Empagliflozin was associated with a nearly 40% reduced risk of incident renal stone disease vs placebo in a large analysis of data pooled from randomized clinical trials.

How to Identify & Evaluate Chronic Kidney Disease Using eGFR and UACR: In brief
June 15, 2022

Primary care clinicians are critical to screening and caring for CKD. This "In brief" slide show reviews the 2 key lab tests used to diagnose the disease.

Finerenone Cardiorenal Effects in T2D Consistent Across Baseline HbA1c, Disease Duration
June 07, 2022

ADA 2022: The protective effect of finerenone on cardiovascular and renal outcomes was not affected by initial HbA1c levels or T2D duration in analysis of data from the FIDELITY pooled cohort.

Kidney Outcomes with Tirzepatide in T2D: Hiddo Heerspink, PhD, PharmD Highlights SURPASS-4 Analysis
June 06, 2022

ADA 2022: Professor Hiddo Heerspink led the prespecified SURPASS-4 analysis that found tirzepatide associated with a 41% reduction in risk of a composite renal outcome.

Tirzepatide Slows Renal Decline in T2D Patients with CKD in First Analysis of Dual Agent on Kidney Function
June 03, 2022

ADA 2022: Tirzepatide, a GIP/GLP-1 receptor agonist, reduced a composite of kidney events in patients with type 2 diabetes and at increased cardiovascular risk in an analysis of SURPASS-4.

National Kidney Foundation Urges USPSTF to Prioritize Screening Recommendation for CKD
May 25, 2022

The USPSTF is rumored to have moved screening for chronic kidney disease to a preventive service it is actively considering and the NFK says, "It's time."

Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
May 25, 2022

Kosiborod, a cardiologist, and Skolnik, a family practitioner, agree no single specialty owns that prescription and that "it takes a village to care for a patient."

SGLT-2 Inhibitors Belong to Patients, Not a Specialty or Primary Care: Experts Discuss
May 18, 2022

Mikhail Kosiborod, MD, a cardiologist and Neil Skolnik, MD, a primary care physician, agree that whoever is seeing the patient should prescribe the drug that is needed.

Study Author Reviews Results: Trends in Time to Initiation of Second-line T2D Treatment
May 05, 2022

Initiation of second-line type 2 diabetes treatment is lagging while A1c at the time it is introduced is climbing. The author of a new study highlights his findings on clinical inertia.